Trials / Completed
CompletedNCT02029859
Sleep Apnea, Obesity and Pregnancy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 205 (actual)
- Sponsor
- University Hospital, Rouen · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Main objective: Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients . Secondary objectives : * Identify risk factors for OSA during pregnancy (age, parity, high blood pressure, snoring , weight, neck circumference, scores on symptoms of sleep apnea, ... ) . * Compare perinatal morbidity among obese patients with OSA in late pregnancy with case-controls. * Evaluate the evolution of a moderate or severe OSA 6 months after pregnancy. Material and methods Characteristics of the study: * Interventional biomedical research * Prospective Multicenter nonrandomized study Flow chart * Patients will be included between 30 and 36 weeks of amenorrhea (WA) . * Will rated from inclusion: age, parity, weight, height, BMI in early pregnancy, neck circumferrence, treated high blood pressure. * As recommended in France, the main test results during the pregnancy follow-up will be recorded. * At the inclusion visit will be conducted a Berlin Questionnaire and Epworth Score. * Screening for OSA by nocturnal polysomnography will be performed between 30 and 36WA. This screening can be performed as an outpatient. * In case of proven OSA patients will be offered an appropriate care by today's standards. * Whatever the outcome of pregnancy, a second polysomnography will be performed 6 months after childbirth in case of OSA during pregnancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Polygraphic examination | Polygraphic examination between 30 and 36 weeks of amenorhea |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2014-07-01
- Completion
- 2015-03-01
- First posted
- 2014-01-08
- Last updated
- 2015-06-03
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02029859. Inclusion in this directory is not an endorsement.